Influenza
Autor(a) principal: | |
---|---|
Data de Publicação: | 2003 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://dx.doi.org/10.1590/S0037-86822003000200011 http://repositorio.unifesp.br/handle/11600/1687 |
Resumo: | Influenza (flu) is an acute contagious viral infection characterized by inflammation of the respiratory tract that every winter affects more than 100 million people in Europe, Japan and the United States of America, also being responsible for several thousand of excess deaths (data from the United States reveal between 20,000 to 40,000 excess deaths annually). The Mixovirus influenzae is the agent that causes influenza, commonly called flu. There are 3 types of influenza virus: A, B, C, and only types A and B are perceived to be clinically relevant in humans. Due to the segmented nature of its genetic material, the influenza virus is highly mutagenic, causing frequent insertion of new antigenic strains into the community, against which the population presents no immunity. Presently, there are few options for the control of influenza and annual immunization is the most effective means to prevent disease and its complications. In Brazil, according to data collected by the VigiGripe's Project - linked to the Federal University of São Paulo -, circulation of the influenza virus also has a seasonal pattern, with peak activity occurring between May and September. Yearly vaccination is, therefore, best indicated on March and April. Currently, there are four medications available for the treatment of influenza viruses: amantadine and rimantadine, and two second generation pharmaceutical products, the neuraminidase inhibitors, oseltamivir and zanamivir. The latter two drugs have set the stage for a new approach to the management and control of influenza infections. |
id |
UFSP_d933ab1911a23bc2ece573b9623537d7 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/1687 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
InfluenzaInfluenzaInfluenzaFluEpidemiologyVaccineTreatmentInfluenzaGripeEpidemiologiaVacinaTratamentoInfluenza (flu) is an acute contagious viral infection characterized by inflammation of the respiratory tract that every winter affects more than 100 million people in Europe, Japan and the United States of America, also being responsible for several thousand of excess deaths (data from the United States reveal between 20,000 to 40,000 excess deaths annually). The Mixovirus influenzae is the agent that causes influenza, commonly called flu. There are 3 types of influenza virus: A, B, C, and only types A and B are perceived to be clinically relevant in humans. Due to the segmented nature of its genetic material, the influenza virus is highly mutagenic, causing frequent insertion of new antigenic strains into the community, against which the population presents no immunity. Presently, there are few options for the control of influenza and annual immunization is the most effective means to prevent disease and its complications. In Brazil, according to data collected by the VigiGripe's Project - linked to the Federal University of São Paulo -, circulation of the influenza virus also has a seasonal pattern, with peak activity occurring between May and September. Yearly vaccination is, therefore, best indicated on March and April. Currently, there are four medications available for the treatment of influenza viruses: amantadine and rimantadine, and two second generation pharmaceutical products, the neuraminidase inhibitors, oseltamivir and zanamivir. The latter two drugs have set the stage for a new approach to the management and control of influenza infections.A influenza (gripe) é doença infecciosa aguda de origem viral que acomete o trato respiratório e a cada inverno atinge mais de 100 milhões de pessoas na Europa, Japão e Estados Unidos, causando anualmente a morte de cerca de 20 a 40 mil pessoas somente neste último país. O agente etiológico é o Myxovirus influenzae, ou vírus da gripe. Este subdivide-se nos tipos A, B e C, sendo que apenas os do tipo A e B apresentam relevância clínica em humanos. O vírus influenza apresenta altas taxas de mutação, o que resulta freqüentemente na inserção de novas variantes virais na comunidade, para as quais a população não apresenta imunidade. São poucas as opções disponíveis para o controle da influenza. Dentre essas, a vacinação constitui a forma mais eficaz para o controle da doença e de suas complicações. Em função das mutações que ocorrem naturalmente no vírus influenza, recomenda-se que a vacinação seja realizada anualmente. No Brasil, segundo dados obtidos pelo Projeto VigiGripe - ligado à Universidade Federal de São Paulo (UNIFESP) -, verifica-se que a influenza apresenta pico de atividade entre os meses de maio e setembro. Assim, a época mais indicada para a vacinação corresponde aos meses de março e abril. Para o tratamento específico da influenza estão disponíveis quatro medicamentos antivirais: os fármacos clássicos amantadina e rimantidina e os antivirais de segunda geração oseltamivir e zanamivir. Os últimos, acrescentam alternativas para o tratamento da influenza e ampliam as opções disponíveis para o seu controle.Grupo de Vigilância Epidemiológica da Gripe Divisão VigiVírusInstituto Adolfo Lutz de São Paulo Seção de Vírus RespiratóriosUniversidade Federal de São Paulo (UNIFESP)UNIFESP, EPM, Sao Paulo, BrazilSciELOSociedade Brasileira de Medicina Tropical - SBMTGrupo de Vigilância Epidemiológica da Gripe Divisão VigiVírusInstituto Adolfo Lutz de São Paulo Seção de Vírus RespiratóriosUniversidade Federal de São Paulo (UNIFESP)Forleo-neto, EduardoHalker, ElisaSantos, Verônica JorgePaiva, Terezinha MariaToniolo Neto, João [UNIFESP]2015-06-14T13:29:58Z2015-06-14T13:29:58Z2003-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion267-274application/pdfhttp://dx.doi.org/10.1590/S0037-86822003000200011Revista da Sociedade Brasileira de Medicina Tropical. Sociedade Brasileira de Medicina Tropical - SBMT, v. 36, n. 2, p. 267-274, 2003.10.1590/S0037-86822003000200011S0037-86822003000200011.pdf0037-8682S0037-86822003000200011http://repositorio.unifesp.br/handle/11600/1687porRevista da Sociedade Brasileira de Medicina Tropicalinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-10-14T13:51:18Zoai:repositorio.unifesp.br/:11600/1687Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-10-14T13:51:18Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Influenza Influenza |
title |
Influenza |
spellingShingle |
Influenza Forleo-neto, Eduardo Influenza Flu Epidemiology Vaccine Treatment Influenza Gripe Epidemiologia Vacina Tratamento |
title_short |
Influenza |
title_full |
Influenza |
title_fullStr |
Influenza |
title_full_unstemmed |
Influenza |
title_sort |
Influenza |
author |
Forleo-neto, Eduardo |
author_facet |
Forleo-neto, Eduardo Halker, Elisa Santos, Verônica Jorge Paiva, Terezinha Maria Toniolo Neto, João [UNIFESP] |
author_role |
author |
author2 |
Halker, Elisa Santos, Verônica Jorge Paiva, Terezinha Maria Toniolo Neto, João [UNIFESP] |
author2_role |
author author author author |
dc.contributor.none.fl_str_mv |
Grupo de Vigilância Epidemiológica da Gripe Divisão VigiVírus Instituto Adolfo Lutz de São Paulo Seção de Vírus Respiratórios Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Forleo-neto, Eduardo Halker, Elisa Santos, Verônica Jorge Paiva, Terezinha Maria Toniolo Neto, João [UNIFESP] |
dc.subject.por.fl_str_mv |
Influenza Flu Epidemiology Vaccine Treatment Influenza Gripe Epidemiologia Vacina Tratamento |
topic |
Influenza Flu Epidemiology Vaccine Treatment Influenza Gripe Epidemiologia Vacina Tratamento |
description |
Influenza (flu) is an acute contagious viral infection characterized by inflammation of the respiratory tract that every winter affects more than 100 million people in Europe, Japan and the United States of America, also being responsible for several thousand of excess deaths (data from the United States reveal between 20,000 to 40,000 excess deaths annually). The Mixovirus influenzae is the agent that causes influenza, commonly called flu. There are 3 types of influenza virus: A, B, C, and only types A and B are perceived to be clinically relevant in humans. Due to the segmented nature of its genetic material, the influenza virus is highly mutagenic, causing frequent insertion of new antigenic strains into the community, against which the population presents no immunity. Presently, there are few options for the control of influenza and annual immunization is the most effective means to prevent disease and its complications. In Brazil, according to data collected by the VigiGripe's Project - linked to the Federal University of São Paulo -, circulation of the influenza virus also has a seasonal pattern, with peak activity occurring between May and September. Yearly vaccination is, therefore, best indicated on March and April. Currently, there are four medications available for the treatment of influenza viruses: amantadine and rimantadine, and two second generation pharmaceutical products, the neuraminidase inhibitors, oseltamivir and zanamivir. The latter two drugs have set the stage for a new approach to the management and control of influenza infections. |
publishDate |
2003 |
dc.date.none.fl_str_mv |
2003-04-01 2015-06-14T13:29:58Z 2015-06-14T13:29:58Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1590/S0037-86822003000200011 Revista da Sociedade Brasileira de Medicina Tropical. Sociedade Brasileira de Medicina Tropical - SBMT, v. 36, n. 2, p. 267-274, 2003. 10.1590/S0037-86822003000200011 S0037-86822003000200011.pdf 0037-8682 S0037-86822003000200011 http://repositorio.unifesp.br/handle/11600/1687 |
url |
http://dx.doi.org/10.1590/S0037-86822003000200011 http://repositorio.unifesp.br/handle/11600/1687 |
identifier_str_mv |
Revista da Sociedade Brasileira de Medicina Tropical. Sociedade Brasileira de Medicina Tropical - SBMT, v. 36, n. 2, p. 267-274, 2003. 10.1590/S0037-86822003000200011 S0037-86822003000200011.pdf 0037-8682 S0037-86822003000200011 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
Revista da Sociedade Brasileira de Medicina Tropical |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
267-274 application/pdf |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Medicina Tropical - SBMT |
publisher.none.fl_str_mv |
Sociedade Brasileira de Medicina Tropical - SBMT |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268455775371264 |